Comparison of the Effect of Pentoxifylline and Captopril on Proteinuria in Patients With Type 2 Diabetes Mellitus. Publisher Pubmed



Aminorroaya A¹ ; Janghorbani M¹ ; Rezvanian H¹ ; Aminian T¹ ; Gharavi M¹ ; Amini M¹ Show Affiliations
Source: Nephron. Clinical practice Published:2005

Abstract

OBJECTIVES: To compare the relative efficacy of pentoxifylline (PTX) and angiotensin-converting enzyme (ACE) inhibitor, captopril in the treatment of proteinuria of type 2 diabetic patients. DESIGN: A randomized open, crossover, clinical trial conducted from October 2000 to March 2001. SETTING AND PARTICIPANTS: 39 patients with type 2 diabetes age 34-75 years were randomly allocated to the two treatment groups. The first group received PTX (400 mg three times a day) orally for a total of 2 months. The second group received captopril (25 mg three times a day) for 2 months. Response to treatment was assessed at 1, 2, 4, and 8 weeks after start of therapy. RESULTS: Captopril appeared to be equivalent in efficacy and safety to PTX. A significant decrease in proteinuria occurred in both groups. Of the 20 patients treated with PTX, the mean (SD) of 24 h urinary protein decreased from 1.4 (0.7) to 1.0 (0.7) g/24 h (p < 0.05). Correspondingly, in the 19 patients treated with captopril, the mean (SD) of 24 h urinary protein decreased from 1.3 (0.7) to 0.8 (0.7) g/24 h (p < 0.01). CONCLUSION: This study demonstrates that treatment with PTX and captopril both significantly reduce overt proteinuria in patients with type 2 diabetes. This effect of ACE inhibition has previously been shown to slow progression to renal failure and we postulate that treatment with PTX may have a similar benefit.